Causes of Cardiovascular Ischemic Events in Giant Cell Arteritis

REFERENCES

1. 1.↵
   1. Weyand CM,
   2. Goronzy JJ

   . Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160–9.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Mohan SV,
   2. Liao YJ,
   3. Kim JW,
   4. Goronzy JJ,
   5. Weyand CM

   . Giant cell arteritis: immune and vascular aging as disease risk factors. Arthritis Res Ther 2011;13:231.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Tomasson G,
   2. Peloquin C,
   3. Mohammad A,
   4. Love TJ,
   5. Zhang Y,
   6. Choi HK,
   7. et al.

   Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med 2014;160:73–80.

   OpenUrlPubMed
4. 4.↵
   1. Larivière D,
   2. Sacre K,
   3. Klein I,
   4. Hyafil F,
   5. Choudat L,
   6. Chauveheid MP,
   7. et al.

   Extra- and intracranial cerebral vasculitis in giant cell arteritis: an observational study. Medicine 2014;93:e265.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Pugnet G,
   2. Sailler L,
   3. Fournier JP,
   4. Bourrel R,
   5. Montastruc JL,
   6. Lapeyre-Mestre M

   . Predictors of cardiovascular hospitalization in giant cell arteritis: effect of statin exposure. A French population-based study. J Rheumatol 2016;43:2162–70.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Gonzalez-Gay MA,
   2. Piñeiro A,
   3. Gomez-Gigirey A,
   4. Garcia-Porrua C,
   5. Pego-Reigosa R,
   6. Dierssen-Sotos T,
   7. et al.

   Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine 2004;83:342–7.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Gonzalez-Gay MA,
   2. Vazquez-Rodriguez TR,
   3. Lopez-Diaz MJ,
   4. Miranda-Filloy JA,
   5. Gonzalez-Juanatey C,
   6. Martin J,
   7. et al.

   Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454–61.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Ly KH,
   2. Régent A,
   3. Tamby MC,
   4. Mouthon L

   . Pathogenesis of giant cell arteritis: more than just an inflammatory condition? Autoimmun Rev 2010;9:635–45.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Diamantopoulos AP,
   2. Haugeberg G,
   3. Lindland A,
   4. Myklebust G

   . The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology 2016;55:66–70.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Bley TA,
    2. Markl M,
    3. Schelp M,
    4. Uhl M,
    5. Frydrychowicz A,
    6. Vaith P,
    7. et al.

    Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology 2008;47:65–7.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Narváez J,
    2. Bernad B,
    3. Roig-Vilaseca D,
    4. García-Gómez C,
    5. Gómez-Vaquero C,
    6. Juanola X,
    7. et al.

    Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 2007;37:13–9.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Saleh M,
    2. Turesson C,
    3. Englund M,
    4. Merkel PA,
    5. Mohammad AJ

    . Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study. J Rheumatol 2016;43:1559–65.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Moiseev S,
    2. Novikov P,
    3. Meshkov A,
    4. Smitienko I

    . Biological agents for giant cell arteritis: treat to target. Ann Rheum Dis 2016;75:e58.

    OpenUrlFREE Full Text
14. 14.↵
    1. Baslund B,
    2. Helleberg M,
    3. Faurschou M,
    4. Obel N

    . Mortality in patients with giant cell arteritis. Rheumatol 2015;54:139–43.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Udayakumar PD,
    2. Chandran AK,
    3. Crowson CS,
    4. Warrington KJ,
    5. Matteson EL

    . Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study. Arthritis Care Res 2015;67:396–402.

    OpenUrlCrossRef
16. 16.↵
    1. Sherer Y,
    2. Shoenfeld Y

    . Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006;2:99–106.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Kermani TA,
    2. Warrington KJ,
    3. Crowson CS,
    4. Ytterberg SR,
    5. Hunder GG,
    6. Gabriel SE,
    7. et al.

    Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2013;72:1989–94.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Labarca C,
    2. Koster MJ,
    3. Crowson CS,
    4. Makol A,
    5. Ytterberg SR,
    6. Matteson EL,
    7. et al.

    Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology 2016;55:347–56.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Nesher G,
    2. Berkun Y,
    3. Mates M,
    4. Baras M,
    5. Rubinow A,
    6. Sonnenblick M

    . Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50:1332–7.

    OpenUrlCrossRefPubMed